Patents by Inventor Hidetaka Seo
Hidetaka Seo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210095012Abstract: The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome. An anti-Sema 3A antibody comprising CDRs having specific amino acid sequences (SEQ ID NOS: 1-6, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86 and 88-90) enables effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome and, therefore, remarkably ameliorates symptoms associated with such a disease.Type: ApplicationFiled: October 7, 2020Publication date: April 1, 2021Inventors: Yoshio Goshima, Fumio Nakamura, Naoya Yamashita, Hidetaka Seo, Shuichi Hashimoto, Koji Murakami, Naoki Takahash, Yukie Sasakura
-
Patent number: 10836814Abstract: The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome. An anti-Sema 3A antibody comprising CDRs having specific amino acid sequences (SEQ ID NOS: 1-6, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86 and 88-90) enables effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome and, therefore, remarkably ameliorates symptoms associated with such a disease.Type: GrantFiled: December 19, 2017Date of Patent: November 17, 2020Assignees: YOKOHAMA CITY UNIVERSITY, CHIOME BEOSCIENCE INC.Inventors: Yoshio Goshima, Fumio Nakamura, Naoya Yamashita, Hidetaka Seo, Shuichi Hashimoto, Koji Murakami, Naoki Takahashi, Yukie Sasakura
-
Publication number: 20180208644Abstract: The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome. An anti-Sema 3A antibody comprising CDRs having specific amino acid sequences (SEQ ID NOS: 1-6, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86 and 88-90) enables effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome and, therefore, remarkably ameliorates symptoms associated with such a disease.Type: ApplicationFiled: December 19, 2017Publication date: July 26, 2018Inventors: Yoshio Goshima, Fumio Nakamura, Naoya Yamashita, Hidetaka Seo, Shuichi Hashimoto, Koji Murakami, Naoki Takahashi, Yukie Sasakura
-
Patent number: 9879075Abstract: The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome. An anti-Sema 3A antibody comprising CDRs having specific amino acid sequences (SEQ ID NOS: 1-6, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86 and 88-90) enables effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome and, therefore, remarkably ameliorates symptoms associated with such a disease.Type: GrantFiled: February 6, 2014Date of Patent: January 30, 2018Assignee: Yokohama City University and Chiome Bioscience Inc.Inventors: Yoshio Goshima, Fumio Nakamura, Naoya Yamashita, Hidetaka Seo, Shuichi Hashimoto, Koji Murakami, Naoki Takahashi, Yukie Sasakura
-
Patent number: 9587251Abstract: The present invention provides a method for obtaining diverse novel genes by inducing somatic cell homologous recombination at genetic loci in somatic cells. By controlling transcription activity of a gene that exists at a genetic locus in a eukaryotic organism cell wherein DNA homologous recombination is occurring at an arbitrary genetic locus, somatic cell homologous recombination is induced between said gene and a gene having a DNA sequence similar to said gene that exists in a region upstream of a transcription promoter, whereby it is possible to obtain diverse novel genes having a plurality of genetic information.Type: GrantFiled: December 22, 2003Date of Patent: March 7, 2017Assignees: Riken, Chiome Bioscience, Inc.Inventors: Kunihiro Ohta, Hidetaka Seo, Takehiko Shibata
-
Publication number: 20150368327Abstract: The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome. An anti-Sema 3A antibody comprising CDRs having specific amino acid sequences (SEQ ID NOS: 1-6, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86 and 88-90) enables effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome and, therefore, remarkably ameliorates symptoms associated with such a disease.Type: ApplicationFiled: February 6, 2014Publication date: December 24, 2015Inventors: Yoshio Goshima, Fumio Nakamura, Naoya Yamashita, Hidetaka Seo, Shuichi Hashimoto, Koji Murakami, Naoki Takahashi, Yukie Sasakura
-
Patent number: 9090672Abstract: Disclosed is a method for producing an antibody directed against a protein, particularly a transmembrane protein, expressed on the surfaces of cells. Specifically disclosed is a means for obtaining a desired antibody by mixing cells capable of expressing an antigen protein on the surfaces thereof (i.e., antigen molecule-expressing cells) with an antibody library composed of antibody-expressing cells, viruses or the like, and subsequently concentrating/isolating only components (e.g., antibody-expressing cells, viruses) capable of binding to the antigen molecule-expressing cells from the components (e.g., antibody-expressing cells, viruses) of the antibody library.Type: GrantFiled: December 7, 2009Date of Patent: July 28, 2015Assignee: CHIOME BIOSCIENCE INC.Inventors: Shu-ichi Hashimoto, Donghui Li, Shoko Ishida, Hidetaka Seo, Chika Koyama, Yukiko Banzai, Naoto Harigai, Isao Kohno
-
Patent number: 8187884Abstract: The present invention provides a novel method for obtaining diverse antibodies as a result of markedly enhancing the somatic homologous recombination at an antibody locus in immunocytes. By putting immunocytes in which DNA homologous recombination is occurring at an antibody locus (for example, DT40 cells and the like) into contact and the like with histone acetylase inhibitor and the like (for example, trichostatin A and the like), thereby relaxing the chromatin structure at said antibody locus, somatic homologous recombination at an antibody locus is enhanced, and the production of diverse antibody molecules is made possible. The production of antibodies that bind specifically to antigens from cell populations in which the antibody molecules have been diversified by the enhancement of somatic homologous recombination is made possible by using an appropriate selection method (for example, beads coated with antigen and the like).Type: GrantFiled: June 10, 2010Date of Patent: May 29, 2012Assignees: Riken, Chiome Bioscience, Inc.Inventors: Kunihiro Ohta, Hidetaka Seo, Takehiko Shibata
-
Publication number: 20110306126Abstract: Disclosed is a method for producing an antibody directed against a protein, particularly a transmembrane protein, expressed on the surfaces of cells. Specifically disclosed is a means for obtaining a desired antibody by mixing cells capable of expressing an antigen protein on the surfaces thereof (i.e., antigen molecule-expressing cells) with an antibody library composed of antibody-expressing cells, viruses or the like, and subsequently concentrating/isolating only components (e.g., antibody-expressing cells, viruses) capable of binding to the antigen molecule-expressing cells from the components (e.g., antibody-expressing cells, viruses) of the antibody library.Type: ApplicationFiled: December 7, 2009Publication date: December 15, 2011Applicant: CHIOME BIOSCIENCE INC.Inventors: Shu-ichi Hashimoto, Donghui LI, Shoko Ishida, Hidetaka Seo, Chika Koyama, Yukiko Banzai, Naoto Harigai, Isao Kohno
-
Patent number: 7968339Abstract: The present invention relates to a method for increasing genetic recombination frequency in a genomic DNA and a method for inducing genome rearrangement. Specifically, according to the present invention there are provided: the method for increasing genetic recombination frequency in a cell in which genetic recombination takes place at any sites in the genome, comprising causing a restriction enzyme to be expressed in the cell, inducing transient activation of the restriction enzyme, and then introducing 2 or more double strand cleavages into any genomic DNA of the cell, so as to increase the genetic recombination frequency; the method for inducing genome rearrangement through the use of the above method; and cells each prepared through the use of the above 2 methods.Type: GrantFiled: November 22, 2005Date of Patent: June 28, 2011Assignee: RikenInventors: Kunihiro Ohta, Hidetaka Seo, Kouji Hirota, Takehiko Shibata
-
Publication number: 20110070650Abstract: The present invention provides a novel method for obtaining diverse antibodies as a result of markedly enhancing the somatic homologous recombination at an antibody locus in immunocytes. By putting immunocytes in which DNA homologous recombination is occurring at an antibody locus (for example, DT40 cells and the like) into contact and the like with histone acetylase inhibitor and the like (for example, trichostatin A and the like), thereby relaxing the chromatin structure at said antibody locus, somatic homologous recombination at an antibody locus is enhanced, and the production of diverse antibody molecules is made possible.Type: ApplicationFiled: June 10, 2010Publication date: March 24, 2011Inventors: Kunihiro Ohta, Hidetaka Seo, Takehiko Shibata
-
Patent number: 7776599Abstract: The present invention provides a novel method for obtaining diverse antibodies as a result of markedly enhancing the somatic homologous recombination at an antibody locus in immunocytes. By putting immunocytes in which DNA homologous recombination is occurring at an antibody locus (for example, DT40 cells and the like) into contact and the like with histone acetylase inhibitor and the like (for example, trichostatin A and the like), thereby relaxing the chromatin structure at said antibody locus, somatic homologous recombination at an antibody locus is enhanced, and the production of diverse antibody molecules is made possible. The production of antibodies that bind specifically to antigens from cell populations in which the antibody molecules have been diversified by the enhancement of somatic homologous recombination is made possible by using an appropriate selection method (for example, beads coated with antigen and the like).Type: GrantFiled: July 28, 2003Date of Patent: August 17, 2010Assignees: Riken, Japan Science and Technology AgencyInventors: Kunihiro Ohta, Hidetaka Seo, Takehiko Shibata
-
Publication number: 20080176753Abstract: The present invention relates to a method of selecting a protein specifically binding to a specific ligand. A method of selecting from a diversifying library a protein specifically binding to a ligand of interest, which comprises: a step of allowing proteins existing in the above library to come into contact with the ligand of interest, so as to select proteins binding to the ligand of interest; a step of allowing the obtained proteins to come into contact with a control ligand, so as to determine the presence or absence of the binding ability of the above proteins to the control ligand; and a step of selecting proteins that are determined not to have the binding ability to the control ligand.Type: ApplicationFiled: November 7, 2005Publication date: July 24, 2008Inventors: Kunihiro Ohta, Hidetaka Seo, Takehiko Shibata
-
Publication number: 20080166809Abstract: The present invention relates to a method for increasing genetic recombination frequency in a genomic DNA and a method for inducing genome rearrangement. Specifically, according to the present invention there are provided: the method for increasing genetic recombination frequency in a cell in which genetic recombination takes place at any sites in the genome, comprising causing a restriction enzyme to be expressed in the cell, inducing transient activation of the restriction enzyme, and then introducing 2 or more double strand cleavages into any genomic DNA of the cell, so as to increase the genetic recombination frequency; the method for inducing genome rearrangement through the use of the above method; and cells each prepared through the use of the above 2 methods.Type: ApplicationFiled: November 22, 2005Publication date: July 10, 2008Inventors: Kunihiro Ohta, Hidetaka Seo, Kouji Hirota, Takehiko Shibata
-
Publication number: 20060183225Abstract: The present invention provides a novel method for obtaining diverse antibodies as a result of markedly enhancing the somatic homologous recombination at an antibody locus in immunocytes. By putting immunocytes in which DNA homologous recombination is occurring at an antibody locus (for example, DT40 cells and the like) into contact and the like with histone acetylase inhibitor and the like (for example, trichostatin A and the like), thereby relaxing the chromatin structure at said antibody locus, somatic homologous recombination at an antibody locus is enhanced, and the production of diverse antibody molecules is made possible.Type: ApplicationFiled: July 28, 2003Publication date: August 17, 2006Applicants: Japan Science and Technology, RikenInventors: Kunihiro Ohta, Hidetaka Seo, Takehiko Shibata
-
Publication number: 20060099678Abstract: The present invention provides a method for obtaining diverse novel genes by inducing somatic cell homologous recombination at genetic loci in somatic cells. By controlling transcription activity of a gene that exists at a genetic locus in a eukaryotic organism cell wherein DNA homologous recombination is occurring at an arbitrary genetic locus, somatic cell homologous recombination is induced between said gene and a gene having a DNA sequence similar to said gene that exists in a region upstream of a transcription promoter, whereby it is possible to obtain diverse novel genes having a plurality of genetic information.Type: ApplicationFiled: December 22, 2003Publication date: May 11, 2006Inventors: Kunihiro Ohta, Hidetaka Seo, Takehiko Shibata